Reaction profile

The FDA adverse-event record for neoplasm bleeding

Name: NEOPLASM BLEEDING - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

11 FDA reports name neoplasm bleeding, a lower-volume reaction in the CVM extract (VeDDRA 99938). Plate stamps and neighbourhood peers follow.

#2435 of 2,481
by report volume (all reactions): 11
reports citing this reaction: 63.6%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. NEOPLASM BLEEDING has 11 reports now versus 11 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: −0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to NEOPLASM BLEEDING changes

FDA AER · VeDDRA plate

Code 99938 VOL-TRACE

VOL-TRACE · DEATH-HOT · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 11 reports
DEATH-HOT 63.6%
BOTTOM-DECILE #2435/2481
PHOTO-FINISH ABNORMAL PANCREATIC S…
SPECIES-DOG Dog · 10
DRUG-LEAD Toceranib Phospha… · 3
DESK-WIDE 10 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: ABNORMAL PANCREATIC SPECIFIC LIPASE (PLI) (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around NEOPLASM BLEEDING

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around NEOPLASM BLEEDING

NEOPLASM BLEEDING: high death-coded share in the FDA AER plate

Signature read: 11 reports place NEOPLASM BLEEDING in the lower third of FDA AER volume (#2435 of 2,481). Report volume is lower-third scale: 11 named reports in the openFDA extract. Death-coded share is upper-third: 7 of 11 reports (63.6% of named reports). Nearest volume peer: ABNORMAL PANCREATIC SPECIFIC LIPASE (PLI) (±0 reports). Lead species Dog (10). Lead co-reported drug Toceranib Phosphate (3).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 10

Horse 1

Breeds Most Affected

Retriever - Labrador 2

Bichon Frise 1

Spaniel - Cocker American 1

Dalmatian 1

Warmblood - Dutch 1

Terrier - Cairn 1

Shih Tzu 1

Shepherd Dog - German 1

Dog (unknown) 1

Mixed (Dog) 1

Associated Drugs

Toceranib Phosphate 3

Trilostane 3

Oclacitinib Maleate 3

Prednisone 2

Cyclosporine 1

Carprofen 1

Diphenhydramine Hcl 1

Famotidine 1

Omeprazole 37% Oral Paste 1

Deracoxib 1

Furosemide 1

Metronidazole 1

Clindamycin 1

Omega-3 1

Lysozyme & Lactoferrin 1

Ivermectin/Pyrantel 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for NEOPLASM BLEEDING (#2435 of 2,481 by report volume); death-coded 63.6%. PlainBreed reaction plate · report volume stamp 11 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →